GLP Research Compounds in the UAE: What the Published Science Shows
·4 min read
GLP-class research compounds have become the most-searched category in the UAE peptide market over the past two years. The volume of questions — and the volume of misinformation — both reflect how quickly this space moved from niche research interest to mainstream awareness.
This article covers the compound science and the differences between classes.
01 — What Does "GLP" Actually Mean?
GLP stands for glucagon-like peptide. These are naturally occurring signalling peptides produced in the gut and pancreas in response to nutrient intake. The two most relevant to current research are:
GLP-1 (Glucagon-Like Peptide-1) — secreted by L-cells in the small intestine and colon. GLP-1 stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic receptors to reduce appetite. Its natural half-life is under 2 minutes in plasma.
GIP (Glucose-Dependent Insulinotropic Polypeptide) — secreted by K-cells in the duodenum. GIP potentiates insulin release and, importantly, acts synergistically with GLP-1 at the level of the hypothalamus to amplify appetite suppression beyond what either pathway achieves alone.
Glucagon — the counter-regulatory hormone to insulin. At the concentrations relevant to GLP-class compounds, glucagon receptor activation increases basal metabolic rate and promotes lipolysis, particularly visceral fat.
The generation of GLP-class research compounds is defined by how many of these receptor pathways they engage.
02 — What Is a Dual Agonist? (Tirzepatide)
Tirzepatide is a synthetic dual GIP/GLP-1 receptor agonist — a single molecule engineered to activate both receptor pathways simultaneously. The GIP component is not a minor addition. Research has shown that GIP/GLP-1 co-activation produces substantially greater reductions in body weight in animal models than GLP-1 activation alone, and the Phase 3 clinical trial data for tirzepatide confirms this finding at scale.
Unlike semaglutide (a GLP-1 mono-agonist), tirzepatide engages the GIP pathway, which appears to amplify hypothalamic appetite suppression through a mechanistically distinct route. The combination also produces a different tolerability profile — lower rates of nausea in published trials compared to equivalent-efficacy doses of GLP-1-only compounds.
03 — What Is a Triple Agonist? (Retatrutide)
Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 combination, making it a triple agonist across all three receptor pathways. The glucagon component is significant: glucagon receptor activation increases resting energy expenditure and drives preferential mobilisation of visceral and hepatic fat depots — something that pure GLP-1 or dual GIP/GLP-1 engagement does not achieve to the same degree.
Phase 2 trial data (NEJM, 2023) showed 24.2% mean body weight reduction in the highest-dose arm at 48 weeks — data that represented the highest published efficacy figure for any single research compound at the time of publication. Phase 3 trials are ongoing.
The mechanistic addition of the glucagon pathway distinguishes retatrutide from both single and dual agonists in a meaningful way, particularly for research examining body composition changes beyond total weight.
04 — Amylin Analogues: A Complementary Compound Class
Amylin is a pancreatic peptide co-secreted with insulin. It suppresses appetite through distinct receptor pathways (the calcitonin receptor complex, CALCR/RAMP) that operate independently of GLP-1, GIP, and glucagon receptors. The implication for research is that amylin-pathway activation and GLP-class activation are mechanistically non-redundant — they do not simply duplicate the same effect through different names.
Two long-acting amylin analogues are currently the subject of significant research interest:
Cagrilintide — a once-weekly amylin analogue developed by Novo Nordisk. Phase 3 trial data (REDEFINE 1, 2025) examining cagrilintide in combination with semaglutide showed 22.3% mean weight reduction at 68 weeks, compared to 15.6% for cagrilintide alone and 16.1% for semaglutide alone. The combination effect exceeds what additive independent effects would predict, suggesting genuine receptor-level synergy.
Eloralintide (LY3841136) — a long-acting amylin analogue from Eli Lilly in Phase 2 development. Early data shows appetite suppression via the amylin pathway independent of GLP-receptor engagement, positioning it as a research compound for protocols examining non-GLP mechanisms of energy regulation.
These compounds represent a distinct and growing category in the appetite and metabolism research space. They are not GLP compounds, but they are frequently studied alongside them precisely because the pathways are complementary rather than competing.
